Evidence map›Paper›PMID 38884271›Full record

ArticleNucleic acids research2024

ASH1L guards cis-regulatory elements against cyclobutane pyrimidine dimer induction.

Michelle N Yancoskie, Reihaneh Khaleghi, Anirvinya Gururajan, Aadarsh Raghunathan, Aryan Gupta, Sarah Diethelm, Corina Maritz, Shana J Sturla, Marimuthu Krishnan, Hanspeter Naegeli

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michelle N YancoskieInstitute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich 8057, Switzerland.ORCID 0000-0002-9895-5301
Reihaneh KhaleghiInstitute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich 8057, Switzerland.
Anirvinya GururajanCenter for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad 500032, India.
Aadarsh RaghunathanCenter for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad 500032, India.
Aryan GuptaCenter for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad 500032, India.
Sarah DiethelmInstitute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich 8057, Switzerland.
Corina MaritzInstitute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich 8057, Switzerland.
Shana J SturlaDepartment of Health Sciences and Technology, ETH Zurich, Zurich 8092, Switzerland.ORCID 0000-0001-6808-5950
Marimuthu KrishnanCenter for Computational Natural Sciences and Bioinformatics, International Institute of Information Technology, Hyderabad 500032, India.ORCID 0000-0002-2549-919X
Hanspeter NaegeliInstitute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich 8057, Switzerland.

Funding

Swiss National Science Foundation 189125University of Zurich FK-22-066
6 · The paper itself

Abstract

The histone methyltransferase ASH1L, first discovered for its role in transcription, has been shown to accelerate the removal of ultraviolet (UV) light-induced cyclobutane pyrimidine dimers (CPDs) by nucleotide excision repair. Previous reports demonstrated that CPD excision is most efficient at transcriptional regulatory elements, including enhancers, relative to other genomic sites. Therefore, we analyzed DNA damage maps in ASH1L-proficient and ASH1L-deficient cells to understand how ASH1L controls enhancer stability. This comparison showed that ASH1L protects enhancer sequences against the induction of CPDs besides stimulating repair activity. ASH1L reduces CPD formation at C-containing but not at TT dinucleotides, and no protection occurs against pyrimidine-(6,4)-pyrimidone photoproducts or cisplatin crosslinks. The diminished CPD induction extends to gene promoters but excludes retrotransposons. This guardian role against CPDs in regulatory elements is associated with the presence of H3K4me3 and H3K27ac histone marks, which are known to interact with the PHD and BRD motifs of ASH1L, respectively. Molecular dynamics simulations identified a DNA-binding AT hook of ASH1L that alters the distance and dihedral angle between neighboring C nucleotides to disfavor dimerization. The loss of this protection results in a higher frequency of C->T transitions at enhancers of skin cancers carrying ASH1L mutations compared to ASH1L-intact counterparts.

Indexed as

DNA-Binding ProteinsDNA RepairEnhancer Elements, GeneticHistone-Lysine N-MethyltransferasePyrimidine DimersDNADNA DamageHistonesHumansMolecular Dynamics SimulationPromoter Regions, GeneticTranscription FactorsUltraviolet RaysASH1L protein, humanDNADNA-Binding ProteinsHistone-Lysine N-MethyltransferaseHistonesPyrimidine DimersTranscription Factors

Identifiers

PMID38884271
PMCPMC11317172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.